Endocannabinoid 2-AG reduces fear and anxiety in rats through CB1 and CB2 receptors in a key brain defense region | Research

The takeaway

Boosting 2-AG signaling in the dorsolateral periaqueductal gray reduced fear expression and anxiety-like behavior in rats, working through both CB1 and CB2 receptors, though effectiveness varied by the type of stressor.

Neuroscience researchers interested in endocannabinoid-based approaches to anxiety and fear.

2-AG reduced fear through both CB1 and CB2 in the PAG

What the researchers found

2-AG injected into the dorsolateral PAG reduced contextual fear expression and produced anxiolytic effects in the Vogel conflict test, both dependent on CB1 and CB2 receptor activation. However, the Vogel test required higher doses, and monoacylglycerol lipase inhibitors (which block 2-AG breakdown) were effective only in the fear conditioning test.

Why it matters

2-AG is the most abundant endocannabinoid in the brain, and understanding its anti-anxiety effects in specific brain regions could inform development of targeted anxiolytic drugs that avoid the psychoactive effects of THC.

The numbers in context

2-AG reduced fear in the contextual fear conditioning test and showed anxiolytic effects in the Vogel conflict test, but the latter required higher doses. Monoacylglycerol lipase inhibitors were effective only in the fear conditioning model.

How the study worked

Male Wistar rats received injections of 2-AG or its hydrolysis inhibitors into the dorsolateral periaqueductal gray, then were tested in contextual fear conditioning and Vogel conflict tests. CB1 and CB2 receptor antagonists were used to determine receptor involvement.

What this study cannot tell us

Only male rats tested. Direct brain injection does not reflect realistic drug delivery. Effects varied by anxiety model, suggesting context-dependent action. No behavioral measures of side effects assessed.

How to read the evidence

Well-controlled animal study with receptor-specific analysis, but direct brain injection limits translational value.

When this study was published

Published in 2022.

The bigger picture

While anandamide (the other major endocannabinoid) loses its anxiolytic effect at higher concentrations, 2-AG may offer a more reliable therapeutic window, making it an attractive target for anxiety treatment development.

Questions still open

Would systemic drugs that boost 2-AG work for anxiety without psychoactive effects? Why does 2-AG require different doses for different types of anxiety? Could 2-AG-targeting drugs treat PTSD specifically?

Common questions

What is 2-AG?

2-arachidonoylglycerol (2-AG) is the most abundant endocannabinoid in the brain. It naturally regulates stress responses and defensive behaviors by acting on CB1 and CB2 receptors.

Did 2-AG work equally well for all types of anxiety?

No. It was more effective in reducing conditioned fear (from prior shock experience) than in a test involving ongoing physical stress, where higher doses were needed. This suggests the endocannabinoid system responds differently depending on the type of threat.

Read the original research

Anti-aversive effect of 2-arachidonoylglycerol in the dorsolateral periaqueductal gray of male rats in contextual fear conditioning and Vogel tests.

Behavioural pharmacology, 33(2&3), 213-221

View on PubMed ↗Publisher’s paper ↗

Citation

Brianis, Rayssa C; Lima, Rita C; Moreira, Fabrício A; Aguiar, Daniele C. (2022). Anti-aversive effect of 2-arachidonoylglycerol in the dorsolateral periaqueductal gray of male rats in contextual fear conditioning and Vogel tests.. Behavioural pharmacology, 33(2&3), 213-221. https://doi.org/10.1097/FBP.0000000000000639